A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

Completed · Phase 1/Phase 2

Conditions studied: Broad Solid Tumor

In brief

The purpose of this study is to evaluate the safety and effectiveness of experimental medication BMS-986207 by itself, in combination with Nivolumab, and in combination with both nivolumab and ipilimumab in participants with solid cancers that are advanced or have spread.

Key facts

Study ID

NCT02913313

Run by

Bristol-Myers Squibb

People needed

101

Starts

2016-11-30

Expected to finish

2024-01-25

Last updated by the study team

2025-04-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must have pre-existing or prior programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) results within 3 months of enrollment from testing of tumor tissue; PD-L1 expression must be tumor cell positive ≥ 1% for a participant to be eligible for enrollment
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria; radiographic tumor assessment performed within 28 days before randomization

You may not qualify if…

• Primary central nervous system (CNS) disease, or tumors with CNS metastases as the only site of disease. Controlled brain metastases will be allowed to enroll
• Other active malignancy requiring concurrent intervention
• Uncontrolled or significant cardiovascular disease
• Active, known, or suspected autoimmune disease
• NSCLC without prior treatment in the advanced or metastatic setting (Part 2C)
• Other protocol-defined inclusion/exclusion criteria apply

Where it is running

• Local Institution - 0001 — Hackensack, New Jersey, United States
• Local Institution - 0003 — New York, New York, United States
• Local Institution - 0012 — Philadelphia, Pennsylvania, United States
• Local Institution - 0002 — Philadelphia, Pennsylvania, United States
• Local Institution - 0009 — Pittsburgh, Pennsylvania, United States
• Local Institution - 0010 — Salt Lake City, Utah, United States
• Local Institution - 0023 — CABA, Buenos Aires F.D., Argentina
• Local Institution - 0019 — Córdoba, Córdoba Province, Argentina
• Local Institution - 0022 — Buenos Aires, Distrito Federal, Argentina
• Local Institution - 0006 — Nedlands, Western Australia, Australia
• Local Institution - 0008 — Ottawa, Ontario, Canada
• Local Institution - 0007 — Toronto, Ontario, Canada
• Local Institution - 0021 — Santiago, Santiago Metropolitan, Chile
• Local Institution - 0004 — Kashiwa-shi, Chiba, Japan
• Local Institution - 0005 — Chuo-ku, Tokyo, Japan
• Local Institution - 0017 — Bucharest, Romania
• Local Institution - 0016 — Cluj-Napoca, Romania
• Local Institution - 0018 — Craiova, Romania
• Local Institution - 0015 — Florești, Romania
• Local Institution - 0020 — Singapore, Singapore

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.